Diffuse follicle center lymphoma, unspecified site
ICD-10 C82.50 is a billable code used to indicate a diagnosis of diffuse follicle center lymphoma, unspecified site.
Diffuse follicle center lymphoma (DFCL) is a subtype of non-Hodgkin lymphoma characterized by the proliferation of B-lymphocytes in the follicle center of lymphoid tissue. This condition is often classified under the broader category of follicular lymphomas, which are known for their indolent nature but can transform into more aggressive forms. DFCL typically presents with lymphadenopathy, which may be localized or generalized, and can involve extranodal sites. Patients may also exhibit B-symptoms, including fever, night sweats, and weight loss, which are indicative of systemic involvement. Diagnosis is confirmed through histopathological examination and immunophenotyping, revealing the presence of CD10, BCL6, and BCL2 markers. Treatment protocols often involve a combination of chemotherapy, immunotherapy, and, in some cases, radiation therapy, depending on the stage of the disease and the patient's overall health. Staging is crucial for determining the appropriate treatment approach and involves imaging studies and bone marrow biopsies to assess the extent of disease spread.
Detailed clinical notes including patient history, physical examination findings, laboratory results, and treatment plans.
Diagnosis and management of newly diagnosed DFCL, treatment response evaluation, and management of relapsed disease.
Ensure accurate staging and documentation of any B-symptoms to support treatment decisions.
Comprehensive pathology reports detailing histological findings, immunophenotyping results, and any relevant molecular studies.
Histopathological evaluation of lymph node biopsies and bone marrow samples.
Accurate reporting of immunohistochemical markers is crucial for proper coding.
Used to monitor blood counts during treatment for DFCL.
Document the indication for CBC and any relevant findings.
Hematology specialists should ensure accurate interpretation of results in the context of lymphoma.
Common treatment options include chemotherapy regimens such as R-CHOP, immunotherapy with monoclonal antibodies like rituximab, and radiation therapy for localized disease. Treatment plans are tailored based on the stage of the disease and patient health.
